Skip to content

Takeda Pharmaceutical

US · TAK #400 by market cap Listed 1970
21.77 +0.36 +1.68%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Quant vs Street three independent views, side by side

StockVane factor grade
C-
Momentum strategy signal
Hold
Analyst consensus
Buy

Mostly aligned, one view stands apart.

Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.

Analyst consensus 1 analysts

Buy
Avg price target 50.46 +131.8%
Price target rangecurrent 21.77
Low50.46
Avg50.46
High50.46
Buy 100% Hold 0% Sell 0%
Recent ratings (9)
DateFirmAnalystRatingTarget
2026-11-16 BofA Securities -- Buy 50.46
2026-09-14 BofA Securities -- Buy 42.56
2026-08-13 BofA Securities -- Buy 44.21
2026-08-06 BofA Securities -- Buy --
2026-07-30 BofA Securities -- Buy 19.00
2026-06-04 TD Cowen -- Buy 21.00
2026-03-30 TD Cowen -- Buy 21.00
2026-01-29 TD Cowen -- Buy 18.00
2025-11-21 TD Cowen -- Buy 18.00

Price target trend monthly average, last 3 years

Earnings history price reaction on the day

PeriodReport dateSessionOptions expectedActual move
2027/Q2 2026-10-29 -- ±6.05% -0.69% (in line)
2027/Q1 2026-07-30 -- ±5.84% -2.82% (in line)
2026/Q4 2026-05-13 -- ±10.35% +1.34% (in line)
2026/Q3 2026-01-29 -- ±6.06% +2.88% (in line)
2026/Q2 2025-10-30 -- ±12.71% -3.92% (in line)
2026/Q1 2025-07-30 -- ±7.57% -5.03% (in line)
2025/Q4 2025-05-08 -- ±5.31% -5.25% (in line)
2025/Q3 2025-01-30 -- ±5.26% +2.93% (in line)
2025/Q2 2024-10-31 -- ±10.15% +0.36% (in line)
2025/Q1 2024-07-31 -- -- +1.69%
2024/Q4 2024-05-09 -- ±12.11% +2.37% (in line)
2024/Q3 2024-02-01 -- ±4.11% -1.51% (in line)

"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.

Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.

Takeda Pharmaceutical discussion 0 comments

Add a comment